Last reviewed · How we verify
High Dose VM202
At a glance
| Generic name | High Dose VM202 |
|---|---|
| Also known as | DNA Plasmid, HGF-X7 |
| Sponsor | Helixmith Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy (PHASE2)
- Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High Dose VM202 CI brief — competitive landscape report
- High Dose VM202 updates RSS · CI watch RSS
- Helixmith Co., Ltd. portfolio CI